Climb Bio Stock Book Value Per Share
| CLYM Stock | 2.10 0.17 7.49% |
Climb Bio fundamentals help investors to digest information that contributes to Climb Bio's financial success or failures. It also enables traders to predict the movement of Climb Stock. The fundamental analysis module provides a way to measure Climb Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Climb Bio stock.
Climb | Book Value Per Share |
Climb Bio Company Book Value Per Share Analysis
Climb Bio's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Climb Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Climb Bio is extremely important. It helps to project a fair market value of Climb Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Climb Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Climb Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Climb Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Climb Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Climb Bio is about 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The book value per share for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
Climb Fundamentals
| Net Income | (35.12 M) | ||||
| Total Debt | 2.87 M | ||||
| Total Asset | 110.47 M | ||||
| Retained Earnings | (155.98 M) | ||||
| Working Capital | 107.42 M | ||||
| Net Asset | 110.47 M |
About Climb Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Climb Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Climb Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Climb Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Climb Bio Piotroski F Score and Climb Bio Altman Z Score analysis. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.